<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363985">
  <stage>Registered</stage>
  <submitdate>4/04/2013</submitdate>
  <approvaldate>15/04/2013</approvaldate>
  <actrnumber>ACTRN12613000419763</actrnumber>
  <trial_identification>
    <studytitle>A prospective study to assess the effect of adalimumab on cardiovascular biomarkers in participants with severe chronic plaque psoriasis </studytitle>
    <scientifictitle>An open-label, prospective pilot study evaluating the effect of adalimumab on endothelial function and on cardiovascular biomarkers in severe chronic plaque psoriasis patients eligible for biologic treatment in Australia</scientifictitle>
    <utrn>U1111-1141-4784 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic plaque psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patient who are deemed eligible for adalimumab according to PBS Australia biologics criteria will be administered with 80mg adalimumab subcutaneously at week 0, 40mg at week 1 and 40 mg subcutaneously every other week. Patients are reviewed at week 6, 12 and every 3 months thereafter if they are on treatment with adalimumab. A PASI (Psoriasis assessment severity index) is performed at each visit to monitor response. Patients will remain in treatment indefinitely if they respond to adalimumab.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether there are potential beneficial effects of TNF-inhibition on endothelial function using an EndoPAT </outcome>
      <timepoint>12 weeks post-starting adalimumab</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether there are beneficial effects of TNF-inhibition on known risk factors such as lipids, insulin resistance and blood pressure with blood tests and sphygmomanometer.
</outcome>
      <timepoint>12 weeks post-starting adalimumab</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether ApoB and ApoA-1 testing if a better indicator of cardiovascular abnormalities than the standard measurement of HDL and LDL with blood tests.
</outcome>
      <timepoint>12 weeks post-starting adalimumab</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether the psoriasis activity (PASI score) duration correlates with endothelial function impairment using EndoPAT.</outcome>
      <timepoint>12 weeks post-starting adalimumab</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient who has had severe chronic plaque psoriasis for at least 6 months with no previous exposure to biologics, and is eligible for biologics as per Australian PBS requirements and has been selected to start adalimumab by a dermatologist</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients not starting on adalimumab as their first biological agent or has had prior biologic treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/04/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3050 - Royal Melbourne Hospital</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Anna Braue</primarysponsorname>
    <primarysponsoraddress>Dermatology Unit, The Royal Melbourne Hospital
Grattan Street,
Parkvilled
VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AbbVie Pty Ltd</fundingname>
      <fundingaddress>Locked Bag 5029, Botany NSW 1455</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, single-centre study of adalimumab in participants with severe chronic plaque psoriasis and eligible for biologic treatment as per Australian Pharmaceutical benefits Scheme (PBS) criteria. We hope this study confirms our hypothesis that patients treated with adalimumab for a 12 weeks period will have improved endothelial function compared to pre-treatment score.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Royal Melbourne Hospital
Parkville Victoria 3050</ethicaddress>
      <ethicapprovaldate>17/10/2012</ethicapprovaldate>
      <hrec>2012.097</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Anna Braue</name>
      <address>The Royal Melbourne Hospital
Parkville
VICTORIA 3050</address>
      <phone>+61393424531</phone>
      <fax />
      <email>Anna.Braue@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephanie Tan</name>
      <address>The Royal Melbourne Hospital
Parkville
VICTORIA 3050</address>
      <phone>+61393424531</phone>
      <fax />
      <email>Stephanie.Tan@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephanie Tan</name>
      <address>The Royal Melbourne Hospital
Parkville
VICTORIA 3050</address>
      <phone>+61393424531</phone>
      <fax />
      <email>Stephanie.Tan@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephanie Tan</name>
      <address>The Royal Melbourne Hospital
Parkville
VICTORIA 3050</address>
      <phone>+61393424531</phone>
      <fax />
      <email>Stephanie.Tan@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>